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Abstract 47 
Since the G8 Dementia Summit in 2013, a number of initiatives have been established with the aim 48 
of facilitating the discovery of a disease-modifying treatment for dementia by 2025. This report is a 49 
summary of the findings and recommendations of a meeting titled ‘Tackling gaps in developing life-50 
changing treatments for dementia’, hosted by Alzheimer’s Research UK in May 2018. The aim of the 51 
meeting was to identify, review and highlight the areas in dementia research that are not currently 52 
being addressed by existing initiatives. It reflects the views of leading experts in the field of 53 
neurodegeneration research challenged with developing a strategic action plan to address these 54 
gaps and make recommendations on how to achieve the G8 Dementia Summit goals. The plan calls 55 
for significant advances in: (1) translating newly identified genetic risk factors into a better 56 
understanding of the impacted biological processes; (2) enhanced understanding  of selective 57 
neuronal resilience to inform novel drug targets; (3) facilitating robust and reproducible drug target 58 
validation; (4) appropriate and evidence-based selection of  appropriate subjects for proof-of-59 
concept clinical trials; (5) improving approaches to assess  drug-target engagement in humans; and 60 
(6) innovative approaches to conducting clinical trials if we are able to detect disease 10-15 years 61 
earlier than we currently do today.  62 
Keywords: Alzheimer’s disease; Dementia; Disease-modifying treatment; Earlier detection; 63 
Diagnosis; Neurodegeneration; Target validation; Clinical trials; Genetic risk factors 64 
1. Introduction 65 
Alzheimer’s disease (AD), and other diseases that cause dementia, are the greatest health and social 66 
care challenges of our age [1]. Today, there are 50 million people living with dementia worldwide 67 
and this is projected to increase to 135 million by 2050 due to a rise in life expectancy and an ageing 68 
population [2, 3]  Current therapeutics for AD can transiently improve cognitive symptoms in some 69 
patients, but they do not treat the underlying causes of dementia or slow the rate of disease 70 
progression [3, 4]. Since the success rate for the development of disease-modifying drugs for 71 
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dementia diseases has been disappointing, such as the failure of beta-secretase 1 inhibitors to show 72 
efficacy, it is important to reconsider what the real barriers to progress in this field are and identify 73 
emerging opportunities. It is intended that this analysis should inform the development of a 74 
strategic action plan that will contribute to the G8 ambition of delivering a disease-modifying 75 
treatment for dementia by 2025, and support progress towards and beyond this goal [3]. 76 
2. Background 77 
In December 2013 the UK government hosted the G8 Dementia Summit to enable the members of 78 
the constituent countries to discuss and formulate an international approach to the global challenge 79 
of dementia [5]. The G8 stated that dementia research should be made a global priority with a key 80 
aim of developing a cure or disease-modifying therapy by 2025 [3, 5]. During the Summit, it was also 81 
agreed that dementia research was under resourced and funded [5]; this has subsequently led to the 82 
establishment of a number of important research initiatives aimed at addressing this specific 83 
challenge [6-10].  For example in the UK, in 2015, the UK Government published the ‘Challenge on 84 
Dementia 2020’, an iteration of the 2012 Dementia Challenge, outlining the government’s aims to 85 
improve dementia care, support and research by 2020 [6]. To meet this challenge in the UK the 86 
Medical Research Council (MRC), part of UK Research and Innovation, founded the Dementias 87 
Platform UK (DPUK) [7] in 2014 with £50 million support for coordinated data and clinical research 88 
infrastructures and experimental medicine collaborations with industry. The Dementia Discovery 89 
Fund [8] was established in 2015 as a global venture capital fund with the aim of investing in new 90 
and emerging disease-modifying therapeutic approaches and facilitating the progression of potential 91 
new drug targets through to early clinical development and testing. Also in 2015, the Drug Discovery 92 
Alliance (DDA) [9] was launched by Alzheimer’s Research UK (ARUK), bringing together three 93 
institutes (University of Cambridge, University of Oxford and University College London) with the aim 94 
of bridging the gap between discovery science and drug development. In addition, the UK Dementia 95 
Research Institute (UK DRI) [10] was founded in 2016, comprising six centres within universities 96 
across the UK, with £290 million of co-funding from the MRC, ARUK and the Alzheimer’s Society. 97 
5 
 
Together, the DDA, DPUK and UK DRI aim to transform the treatment, care, prevention and 98 
diagnosis of dementia, through coordinated discovery science and translation to people living with 99 
dementia. 100 
Despite these and other efforts, significant gaps still exist that hamper the development of disease-101 
modifying treatments for dementias. To address these gaps, ARUK convened a panel of experts in 102 
the dementia field, including global academic and industry researchers, to identify and prioritise key 103 
thematic areas that are not the current focus of research and funding initiatives in this field. During 104 
15 and 16 May 2018 the panel met in London, UK to discuss how to tackle each specific gap and 105 
develop an action plan around each theme. The action plan was intended to be future looking, to 106 
provide important information to facilitate the progress of dementia research and ultimately inform 107 
and direct the development of life-changing treatments for dementia. 108 
The meeting was organised around six themes: (1) translating genetic risk factors into biological 109 
processes; (2) better understanding neuronal resilience to inform novel drug targets; (3) facilitating 110 
robust and reproducible drug target validation; (4) identifying appropriate populations of 111 
appropriate subjects for Phase IIa proof-of-concept clinical trials; (5) improving approaches to assess 112 
drug-target engagement in humans; and (6) innovative approaches to conducting clinical trials if we 113 
are able to detect dementia diseases 10-15 years earlier than we are able to today. Each theme will 114 
be reviewed in this paper and the key recommendations are outlined.  We also include a preliminary 115 
action plan to attempt to begin to address and resolve these recommendations. 116 
3. Translating genetic risk factors into biological processes  117 
Understanding genetic vulnerability and its impact on neuronal health and biology 118 
Important advances have been made in identifying genetic factors that contribute to the risk of 119 
developing diseases that may cause dementia, and particularly AD. Mutations in amyloid precursor 120 
protein and presenilin 1 and 2 cause autosomal dominant AD, and the apolipoprotein E (APO E) ε4 121 
allele is a major risk-factor for late onset AD [11]. A key goal of current AD research is to seek out 122 
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novel disease-risk genes, elucidate their biological function in the development of the disease and 123 
try to interpret important gene-gene or gene-environment interactions with the aim of identifying 124 
novel approaches to the treatment and prevention of AD and other neurodegenerative diseases. The 125 
standard method for identifying disease-risk genes has been genome-wide association studies 126 
(GWAS), and this approach has led to the identification of (at least) an additional 21 genetic risk loci 127 
[12]. However, these are highly complex diseases likely caused by the composite action of multiple 128 
disease-related genes.  This compounds the challenge of translating  genetic findings into functional 129 
mechanisms that are important in disease pathogenesis [12] and consequently, valid targets for the 130 
development of effective therapeutics.  Discussions in this session focussed on approaches to 131 
improve the translation of genetic findings into disease biology using a more integrated biology 132 
approach, better tools and analysis of genotype-phenotype correlations to provide a more 133 
comprehensive understanding of disease causation and inform future therapeutic drug discovery 134 
and biomarkers.   135 
As many genetic factors having been identified as contributing to the risk for developing AD, the 136 
research focus has shifted from identifying novel risk factors toward understanding how such risk 137 
factors lead to changes in biological processes and pathways, some of which are already known to 138 
be affected in dementing and other neurodegenerative diseases. Moving from genetic data to a 139 
potential therapeutic will involve different tools and areas of expertise, including in silico and 140 
laboratory approaches to structural biology, cell biology, and pharmacology. Leveraging emerging 141 
technologies (such as single cell studies or induced pluripotent stem cell models) will also enable 142 
acceleration of the investigation of the links between genetic data and potential therapeutics.  The 143 
Open Targets partnership is a good example of this approach [13]. It brings together expertise from 144 
six different institutions and uses human genetics and genomics data to systematically identify and 145 
prioritise drug targets for therapeutic development [13]. Another good example is seen in 146 
schizophrenia research, where understanding the role of the complement component 4 locus 147 
involved the application of different tools and datasets (including GWAS and expression data from 148 
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post-mortem brains), and genetic engineering of animal models to understand the biological 149 
mechanism [14]. This approach identified potential biological targets from genetic data that may 150 
result in the development of novel therapeutics. These examples of partnerships and collaborations, 151 
and application of different tools, should be more widely adopted by the dementia research 152 
community to bridge the gap between genetic signals to biologically relevant therapeutic targets. 153 
Interdisciplinarity and development/application of a broad range of tools and technologies are also 154 
at the heart of the UK DRI research network, aiming to accelerate our mechanistic understanding of 155 
dementia to find new ways to prevent, diagnose and treat dementia effectively [10]. 156 
A significant challenge in translating genetic data into biological processes is the lack of 157 
understanding of the underlying role of individual genes, and how they relate to disease progression 158 
and phenotype in later life. Genomic analysis across the natural history of the disease would enable 159 
a better understanding of the genes involved at different stages of disease, provide additional 160 
insight into the disease mechanism(s) and inform the development of alternative interventions or 161 
new areas of research. Part of this genetic analysis should also include identification of the genetic 162 
influences on rate of disease progression. This could be approached by capitalising on longitudinally 163 
phenotyped cohorts that include and contrast subjects with sporadic AD to analyse the genotype-164 
phenotype interactions and progression of the disease. 165 
To support these approaches, it will be important to identify key expertise from different disciplines 166 
that are currently missing from dementia research and proactively engage with subject matter 167 
experts from diverse areas such as data science, not only to bring that expertise into the dementia 168 
field but also to promote the exchange of knowledge and innovation. Barriers to collaborative and 169 
interdisciplinary research also need to be understood and addressed. For example, intra-institutional 170 
collaborations may have been hindered in the UK by the fact that a publication could only be 171 
submitted once to the former Research Excellence Framework assessments from each institution 172 
[15]. The evaluation of collaborative research outputs has changed, with a greater emphasis on 173 
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impact and contribution, but further changes in the evaluation and recognition process are needed if 174 
we are to foster true collaborative efforts. 175 
There is also a need to bring together experts from other relevant disease and basic science areas of 176 
expertise, particularly those shown to have an increasingly important role in dementia research (e.g.  177 
immunologists and lipid biologists), and to encourage intra- and interdisciplinary collaboration. This 178 
approach has been successful in Huntington’s disease research, where the CHDI Foundation 179 
(https://chdifoundation.org/) manages a network of over 600 researchers worldwide, facilitating the 180 
sharing of ideas and information that encourages active collaboration. A similar model could be 181 
adopted for dementia research. Dementia symposia and workshop sessions could be included in 182 
conferences hosted by other disciplines, such as immunology and oncology. Similarly, subject matter 183 
experts in relevant fields could chair these symposia or workshops (e.g. asking immunologists to lead 184 
neuroinflammation discussions).  Such approaches would encourage cross-discipline fertilisation and 185 
potentially bring new expertise into the dementia field.  186 
This approach has been adopted by the DPUK for experimental medicine working groups, and the 187 
Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer’s Disease 188 
(NIMA) [16]. The NIMA Consortium is investigating novel therapeutic and biomarker approaches for 189 
neurodegeneration based on the biological links between inflammation and neurodegeneration and 190 
a number of clinical compounds derived from immunology drug discovery. To address this challenge, 191 
the Consortium assembled a team of academic and industry scientists with diverse expertise in 192 
imaging, animal models, clinical phenotyping and informatics. Such collaborative and 193 
interdisciplinary approaches could facilitate the translation of genetic research that impacts on cell 194 
biology into neurodegenerative research and development. 195 
 196 
 197 
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Summary of recommendations and suggested actions 198 
3.1.1. Facilitate translation of genetic risk factors into targetable biological processes and 199 
pathways using a more integrated biology approach 200 
3.1.2. Support the application of tools and expertise from other fields to better translate 201 
genetic information into cell biology and drug development 202 
3.1.3. Encourage research that seeks to carry out genomic analysis along disease 203 
progression to identify the genes involved at different stages of disease 204 
3.1.4. Support interdisciplinary collaboration, and the development of dementia symposia 205 
and workshop sessions in other relevant disciplines to foster cross-fertilisation of ideas 206 
and bring new expertise into the dementia field. 207 
 208 
4. Better understanding selective neuronal vulnerability and resilience to inform 209 
novel drug targets  210 
Could a better understanding of why some neurones die and others are resistant to cell 211 
death identify novel drug targets? 212 
This session was focused on why some neuronal cell populations die very early in the course of the 213 
disease, others die at a later stage and still others do not seem to degenerate at all, and whether 214 
understanding this difference could help identifying novel targets for drug development. Recent 215 
research has identified multiple neurodegenerative pathways that result in a domino-like cascade of 216 
events that eventually lead to the development of dementias. However, these changes are not seen 217 
in all cases of AD [17, 18]. The characteristic features of AD are the pathological accumulation of 218 
extracellular plaques composed of amyloid-β protein and intraneuronal tangles consisting of altered 219 
forms of tau [17].  A long-standing puzzle in AD research has been the finding that there may be a 220 
substantial number of Aβ plaques in the brain of some individuals who have otherwise normal 221 
cognition and conversely people who exhibit phenotypic AD but have little or no plaque or tangle 222 
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deposition [19, 20]  Studies show that Aβ deposition is an early event that may play a harmful role in 223 
the development of AD, however, the mechanisms that link Aβ to neurodegeneration are poorly 224 
understood. Moreover, intermediate A species (e.g. oligomers) perhaps contribute more to nerve 225 
injury than to plaques [21]. Clinically relevant symptoms tend to emerge around the same time that 226 
tau pathology is correlated with cell death, although it is also acknowledged that the intermediate 227 
oligomeric species may play a critical role in such developments [22]. Moreover, some brain regions 228 
(hippocampus, amygdala and cerebral cortex) appear to show a selective vulnerability to plaque 229 
accumulation and tau associated neurodegeneration, while others (basal ganglia, cerebellum, brain 230 
stem and spinal cord) are initially spared [23, 24].  231 
These observations suggest that understanding why some brain structures are more vulnerable to 232 
insults than others could be gained by examining the molecular differences between neurones that 233 
are susceptible to neurodegeneration and those that are relatively protected. For example, 234 
excitatory but not inhibitory neurons, that differ in their expression of proteins that enable protein 235 
degradation, accumulate damaging tau aggregates in a genetically engineered mouse model of tau 236 
pathology spread [25]. This type of approach may aid the identification of novel disease mechanisms 237 
that could be exploited to develop alternative therapeutic targets for disease management with a 238 
potentially higher success rate for treatment.  For example, recent studies have explored the locus 239 
coeruleus, a brainstem nucleus in the central nervous system (CNS) that is the primary site for 240 
production of noradrenaline and has diffuse noradrenergic innervation. Noradrenergic neurons in 241 
this region play a central role in normal cognitive function, and so loss of innervation in this region is 242 
postulated to be linked to cognitive decline, suggesting that noradrenaline signalling in the CNS 243 
might be a viable therapeutic target [26].  244 
The key advance enabling this approach was the possibility of biologically mapping the molecular 245 
signature of different neuronal populations in healthy brains versus brains from subjects with 246 
neurodegenerative diseases. This may lead to a better understanding of the biological processes 247 
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associated with neuronal vulnerability and may allow for a spatial and chronological characterisation 248 
of the neural cell systems affected in dementia. The Allen Institute is making progress in this area, 249 
with a project entitled Aging, Dementia and Traumatic Brain Injury Study [27] within the Allen Brain 250 
Atlas [28]. It would be very useful to explore and expand the potential of these projects by 251 
integrating data from different research groups globally. This requires overcoming barriers to data 252 
sharing, data accessibility and integrative approaches across institutions to enable 253 
interconnection/interoperability and linkage of datasets. A complementary approach to mapping 254 
neuronal vulnerability has also been suggested at the National Institute of Health AD Summit 2018 255 
[29] to develop an AD connectivity map based on ‘omics’ expression signatures in disease-relevant 256 
cell types.  Further investigation using an omics-based approach could systematically map resilience 257 
and vulnerability by brain region as well as tracking the trajectory of the disease [30]. Integrating 258 
multiple sets of omics data using computational and statistical tools can be used to analyse the 259 
molecular pathways in specific brain regions and perhaps identify the more vulnerable pathways. 260 
Others have suggested that additional approaches are needed, such as a more active investigation of 261 
glia and vascular changes [31]. 262 
This could be studied using longitudinal structural magnetic resonance imaging (MRI) or synapse 263 
positron-emission tomography (PET) imaging, however another important aspect is the evaluation of 264 
post-mortem or resected human tissue, something that is not necessarily straightforward to obtain 265 
from well characterised cases and without significant post-mortem delay, required for high-quality 266 
samples. It was proposed that researchers need better access to living tissue from people living with 267 
dementia, and the panel recommended that this be achieved by enabling access to resected tissue 268 
from surgeries and utilising excess biopsy tissue. One approach suggested to streamline access was 269 
through the UK Brain Banks Network, a coordinated national network of UK brain tissue resources 270 
for research purposes [32]. It would be important for neurosurgeons to follow a standard operating 271 
procedure (SOP) in order to facilitate the collection of high-quality tissue for the brain banks and so 272 
it was proposed to develop SOPs in collaboration with the MRC Brain Bank Initiative and to identify 273 
12 
 
best practice globally. It was also suggested that the Brain Bank Steering Committee engage with 274 
cohort principal investigators to encourage them to obtain consent for the use of brain tissue for 275 
research purposes. Other suggestions included encouraging pre-consenting for people living with 276 
dementia in clinical trials for post-mortem brain donation, collaborating more closely with 277 
neurosurgeons, and standardising brain tissue processing in order to maintain its usefulness for 278 
study (e.g. rapid cooling of excised brain tissue). 279 
Finally, dementia research organisations can set the agenda, drive research and encourage 280 
collaboration by sharing of information with the wider research community [33]. Pre-clinical 281 
biological data can often be difficult to disseminate in an accessible format, due to the unstructured 282 
nature of certain data sets, for example omics type data and imaging. Developing solutions for data 283 
sharing and accessibility may enable the field to progress at a faster rate.  284 
Summary of recommendations and suggested actions 285 
4.1 Use an omics-based approach, and others such as imaging, to map resilience and 286 
vulnerability by brain region including all cell types to better understand disease 287 
processes, characterise disease trajectory, and potentially yield novel targets for drug 288 
discovery 289 
4.2 Access to tissue 290 
4.2.1 Generate neurosurgical SOPs to enable research access to excess biopsy tissue 291 
and resected tissue from neurosurgery, where undertaken for clinical 292 
indications 293 
4.2.2 Encourage pre-consenting for those in trials for post-mortem brain donation 294 
and ensure procedures are in place to optimise this process (e.g. enforce 295 
procedures to ensure rapid brain cooling at time of death). 296 
 297 
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5. Robust and reproducible target validation 298 
The need to improve validation of potential drug targets 299 
Currently only symptomatic treatments for dementia are available. At best, they transiently provide 300 
limited cognitive benefit in approximately 40% of people living with dementia, and they have no 301 
impact on the underlying disease processes or the rate of cognitive decline [3, 4]. While 302 
development of symptomatic treatments has slowed, the search for dementia preventing or 303 
modifying treatments has increased significantly [34].  304 
A plethora of innovative approaches to drug discovery are emerging, with the identification of 305 
putative novel mechanisms and potential drug targets being published in high profile journals. 306 
However, robust and reproducible biological validation of potential new molecular targets is key to 307 
successful and productive drug discovery.  It is critical that exciting early published findings can be 308 
reproduced across different model systems and laboratories to provide confidence when moving 309 
from laboratory to clinic.  However, translating these early novel biology findings into robust drug 310 
target validation is often met with failure and there are still many significant barriers to successful 311 
drug development. The reasons for this are many fold, including incentives to publish pre-clinical 312 
work without the necessary robust evidence for relevance of applicability to human disease; 313 
fundamental differences in the biology and degeneration of brain cells in different species; and 314 
limitations in the human disease models and outcomes. Incentives to publish novel findings as 315 
rapidly as possible detracts from reproducing initial novel findings either within the same academic 316 
lab or in independent labs. Grant funding does not always readily allow the reproduction of findings 317 
in different in vitro and in vivo models, and validation data are less attractive to publishers. In 318 
addition, the pressure on both academic and biotech researchers to progress targets rapidly to the 319 
next stage of development does not necessarily support robustness or establishing cross-species 320 
homologies. Whilst these issues are not confined to dementia research, the current paradigm for 321 
target validation in neurodegenerative research should be strengthened significantly with an 322 
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emphasis on both robustness and reproducibility of early preclinical experimental methodology and 323 
findings.  324 
Significant effort is required to address these issues with emphasis on training and awareness (e.g. 325 
scientists trained in pharmacology and rigorous experimental design including robust statistics). High 326 
quality collaborative and interdisciplinary proposals should be incentivised, to encourage research 327 
groups working on identical/similar targets can share their expertise, minimise risk and cost and 328 
improve robustness and reproducibility through integration of diverse disciplines. There was also 329 
consensus that incentivising validation of potential drug targets through cross verification from two 330 
or more sources, for example bioinformatics data, genetics, cell biology in vitro and in vivo and real-331 
world observational data would result in significant long-term benefits.   332 
 The results of an interesting discussion on facilitating reproducibility and robustness of early 333 
experimental findings focussed on the expertise of independent grant review. It was proposed that 334 
high quality grant review could be achieved by the following: (1) encouraging wider expertise from 335 
other fields to participate in the grant peer review process; (2) provide detailed and constructive 336 
feedback, which can help researchers better understand how to achieve robust target validation; 337 
and (3) use of good practice guidelines that can be shared across the scientific community.  338 
Examples of good practice methodology could be collated in order to develop the guidelines for drug 339 
target validation similar to the Animal Research Reporting In Vivo Experiments (ARRIVE) guidelines 340 
[35] or the Organization for Human Brain Mapping’s Committee on Best Practice in Data Analysis 341 
and Sharing [36]. 342 
Incentives to researchers have not always supported robustness and reproducibility of data, where 343 
tenure and promotion structures have placed great emphasis on novel, high impact research, which 344 
may have high impact, but risks unreproducible outputs based on a limited number of experiments. 345 
Therefore, the incentive structure and training should be reconfigured to also promote validation of 346 
results. It is important to raise awareness and incentivise drug target validation and translation as a 347 
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critical process of drug development for example, encouraging researchers to conduct experiments 348 
that provide predefined ‘NoGo’ decision endpoints in a research proposal, effectively rewarding the 349 
termination of futile lines of enquiry. These proposals could be adopted readily and included in the 350 
guidelines for grant applications and could be an additional criterion for review.   351 
Wider dissemination of information on ineffective technologies/techniques and publishing of 352 
negative results should also be supported. This could be achieved through funders encouraging open 353 
research platforms (e.g. AMRC Open Research https://amrcopenresearch.org/, Wellcome Trust 354 
Open Research https://wellcome.ac.uk/what-we-do/our-work/open-research, and Alzforum 355 
https://www.alzforum.org/) to publish data that might otherwise not be published by peer reviewed 356 
journals (e.g. negative data). This would enable more timely ‘Go’/’NoGo’ decisions to be made, and 357 
streamline the translational pipeline. 358 
The drug target validation process is at the interface between academia and industry, and promoting 359 
better collaboration between the two can lead to a better understanding of the basic science of AD 360 
and the requirements for drug development. This will ultimately improve and enhance the validation 361 
of novel biological findings. Progress in this area has been made through initiatives such as ARUK’s 362 
Drug Discovery Alliance and Dementia Consortium [37], as well as the US initiative Accelerating 363 
Medicines Partnership - Alzheimer's Disease (AMP-AD) [38], although more needs to be done to 364 
expand this and other collaboration models to additional institutions and countries.  365 
The translation of laboratory-based findings to clinically relevant therapies is very complex. Pre-366 
clinical testing of potential new therapies for AD and other neurodegenerative disorders relies on 367 
effective animal models of disease or disease mechanisms that have both face and construct validity. 368 
Whilst all animal models have their limitations, a number of established and accepted 369 
pharmacodynamic animal models, based on familial mutations in AD, are now used widely to 370 
support dementia research.  However, even with these select number of models, there is extensive 371 
variability in the design of animal experiments between different research groups. This results in 372 
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animal models with varying characteristics, which ultimately leads to lack of consistent validation. 373 
Compounding the issue, is the lab variability introduced by not using the appropriate background or 374 
control strains. To improve validation, optimised experimental design protocols for animal models in 375 
dementia should be developed and standardised. This should entail an in depth review of existing 376 
models and experimental procedures followed by open publication of standardised animal protocols 377 
and promotion of their use (e.g. preference setting by high profile journals and funding bodies), 378 
similar to the NEWMEDS initiative for schizophrenia research [39].  Scientists working in 379 
osteoarthritis research have recently published ‘considerations for the design and execution of 380 
protocols for animal research and treatment’ [40] to complement the ARRIVE guidelines [35], and a 381 
guide has also been produced for Huntington’s disease animal models [41]. A similar protocol could 382 
be developed and adopted for animal model research in dementia diseases. 383 
Summary of recommendations and suggested actions 384 
5.1.1 Provide training for scientists in areas of skills gaps (e.g. pharmacology, statistics) 385 
and facilitate collaboration 386 
5.1.2 Incentivise validation of potential drug targets through cross-verification with 387 
different sources of data and different experimental systems 388 
5.1.2.1 Funders should require robust validation approaches in funding applications, 389 
with use of multiple data sources/systems and, where appropriate, use of 390 
independent labs 391 
5.1.3 Support the sharing of information on ineffective technologies/techniques and 392 
publishing of negative results 393 
5.1.3.1 Funders should encourage open research platforms (such as Alzforum) to 394 
publish negative data and the scenarios within which they are tested 395 
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5.1.4 Facilitate translation from novel target validation to early drug discovery (e.g. 396 
through models such as the ARUK Dementia Consortium, where expert scientists 397 
from different sectors work together)  398 
5.1.5 Develop an optimised experimental design protocol for animal model research 399 
5.1.5.1 Review experimental design and methodologies and publicise and encourage 400 
use of suggested standardised protocols. 401 
6. Appropriate choice of subject populations for proof-of-concept clinical trials 402 
Who to select for early proof-of-concept clinical trials  403 
Between 2002 and 2012, only one compound of 244 evaluated in clinical trials for AD reached the 404 
market, translating to an overall attrition rate of 99.6% with 98% of those evaluated in Phase III 405 
clinical trials failing to show efficacy [42]. The number of compounds that progress to regulatory 406 
review is among the lowest for any therapeutic area [42]. One of the factors often linked to this high 407 
failure rate is inappropriate selection of subject populations in early clinical trials, leading to results 408 
that fail to translate through to Phase III trials.  A key aim of Phase Ib/IIa studies is to show proof of 409 
pharmacology over a short period of time, and these trials typically restrict inclusion to a very small 410 
fraction of the total pool of people living with dementia (e.g. excluding by common co-morbidities, 411 
or narrow stage of disease). Thus, the typical Phase IIa population of people living with dementia 412 
may not be representative of the wider cohort that is the likely population to be evaluated in Phase 413 
III. For AD it may be beneficial to consider using a more heterogeneous population in Phase IIb trials, 414 
to increase the probability of success in the wider patient populations or to restrict recruitment in 415 
Phase III trials to a population of patients more likely to benefit from a particular treatment.  416 
The current challenge of recruiting appropriate subjects to proof-of-concept clinical trials is complex 417 
given the questions that need to be addressed by early stage studies, i.e. safety and proof of 418 
mechanism/efficacy on disease progression within a relatively short period of time. For evaluation of 419 
an AD therapeutic prodromal AD and/or  early AD may not be the relevant populations, as the time 420 
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taken to show a clear change in cognitive decline is likely to be beyond the reasonable duration of 421 
such trials (typically over 18 months), until a time when there is a consensus on more sensitive 422 
endpoints. Therefore, in order to effectively demonstrate proof of concept, alternative subject 423 
populations could be recruited to these studies, with subsequent studies expanding to include the 424 
AD populations. This strategy relies on the true relevance or functional equivalence of the 425 
alternative population to AD. Such equivalence is often assumed, but rarely proven. For example, 426 
targeting clearly defined populations such as Down’s syndrome or familial AD to demonstrate 427 
mechanistic efficacy could not only facilitate therapeutic proof of concept but also enable the 428 
development of treatments for populations with significant unmet medical need.  If proof of concept 429 
were to be demonstrated in these groups, trials could then be expanded to incorporate the wider 430 
AD population. In both the Down’s syndrome and familial AD populations, Aβ and tau pathology plus 431 
the onset of cognitive impairment follows a path similar to that in sporadic AD, but in both 432 
populations the onset and progression of the disease is more predictable and homogeneous with 433 
less co-morbidity than late onset populations [43, 44].   434 
The aims for research and development in recruiting people with Down’s syndrome, familial AD, and 435 
sporadic AD to a study somewhat differ.  People with Down’s syndrome represent a population in 436 
which to explore the early efficacy of drugs, particularly those targeted against Aβ and tau, which 437 
slow down disease progression.  Almost all people with Down’s syndrome progress to AD and 438 
dementia, with an Aβ pathology which is very similar to that observed in people with AD [43].  Thus, 439 
they represent a population of huge unmet medical need in their own right.  In addition, they 440 
arguably represent a more homogeneous population where the Aβ pathology is well defined and 441 
where drugs can be evaluated for pharmacodynamic effects and early efficacy at a very early stage 442 
in the disease process.  The latter is also arguably the case for familial AD.  However, one important 443 
consideration is that both these populations are different to the majority of people with sporadic or 444 
late onset AD: they are younger, more commonly present with phenotypes other than typical 445 
amnestic mild cognitive impairment AD and have subtly different neuropathology to sporadic AD 446 
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and differences in the role of vascular pathology in pathogenesis. In addition, in people with Down’s 447 
syndrome, the variability in pre-morbid cognitive function raises challenges for outcome measures 448 
and informed consent issues, which is not the case in familial AD. These and other differences may 449 
compromise the predictability of a drug effect, given the non-equivalence to most people with AD.  450 
Even taking this into account, these populations may offer a route to delivering early proof of 451 
efficacy for some compounds and should be considered on a case-by-case basis depending on the 452 
mechanism of treatment.  453 
Alongside this approach, new strategies should be explored to better stratify subjects into clinical 454 
trials. There is a requirement to identify, recruit, characterise and allocate people using clinical study 455 
registers to create dementia cohorts.  One potential solution is using longitudinal phenotyped 456 
clinical registries and readiness cohorts, the current strategy of the DPUK (which includes the Deep 457 
and Frequent Phenotyping study) and European Prevention of Alzheimer’s Dementia (EPAD) 458 
Consortium respectively [45, 46]. Furthermore, there is currently very little information on genetic 459 
factors linked to the rate of disease progression, or phenotypic variance (e.g. amnestic vs. posterior 460 
cortical atrophy vs. logopenic aphasia variants of AD). Large scale and long-term registers allow for 461 
people to be profiled mechanistically and longitudinally, including disease progression, to distinguish 462 
genetic and environmental determinants of fast versus slow progressors, enabling more accurate 463 
stratification for clinical trials. This approach has been informative in Parkinson’s disease and 464 
frontotemporal dementia [47, 48]. 465 
Recruitment of individuals to clinical trials remains low even with the existence of many cohorts and 466 
the above-mentioned registries. In order to improve recruitment to clinical trials, it is important to 467 
understand the barriers and incentives to increase clinical trial participation and to engage with 468 
principal investigators to incentivise the use of cohorts. This is one of the priority areas promoted by 469 
Bill Gates in his plans for investment in AD [49].  One barrier to increasing clinical trial participation 470 
by well characterised subjects within existing cohorts is the mutual exclusivity between longitudinal 471 
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observational phenotyping over several years and therapeutic studies; these activities do not need 472 
to be mutually exclusive, but in practice they often are. To address this issue, it is essential that 473 
participation in research is increased so that both types of studies can coexist without mutual 474 
exclusion. 475 
6.1. Summary of recommendations and suggested actions 476 
6.1.1.  Select relevant populations which best address the questions being asked at the 477 
relevant stage of development i.e. proof of concept/mechanism/pharmacology 478 
6.1.1.1. Focus on mechanism/pharmacology/efficacy in clearly defined populations 479 
initially to allow demonstration of proof of mechanism/pharmacology and 480 
subsequently expand to the wider AD population if appropriate 481 
6.1.1.2. Examples of such populations could be Down’s syndrome or familial AD, 482 
where there are huge unmet medical needs, and pathology is sufficiently similar 483 
to that of sporadic AD, but disease progression is more rapid or more predictable 484 
6.1.1.3. Early proof of concept populations could provide the predictive data 485 
required to expedite the next phases of clinical development 486 
6.1.2.  Consider how to improve genotype-phenotype translation to enable stratification of 487 
people living with dementia for clinical trials 488 
6.1.2.1. A longitudinally phenotyped experimental medicine register could facilitate 489 
this 490 
6.1.2.2. Profile people living with dementia mechanistically and longitudinally along 491 
disease progression to better understand the biology/pathology associated with 492 
fast and slow progressors to enable accurate stratification 493 
6.1.3. Understand barriers and incentives to increasing clinical trial participation and 494 
incentivise the use of cohorts and registries 495 
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6.1.3.1. Longitudinal observational phenotyped cohorts and therapeutic readiness 496 
cohorts are often mutually exclusive but are equally critical for clinical research - 497 
increase participation in research to fill both cohorts. 498 
7. Improving approaches to assess drug-target engagement in humans 499 
Making more informed decisions in clinical development 500 
Prior to neurodegenerative disease therapeutics entering the clinical pipeline they are screened for 501 
their pharmacology, pharmacodynamics, pharmacokinetics and toxicity  in preclinical model 502 
systems. Data from these studies are intended to inform factors such as safety, optimal clinical dose 503 
range, blood-brain barrier penetration and binding to the intended target [50].  Although these 504 
preclinical data are informative they do not fully describe all the clinical findings in early human 505 
trials.  It is therefore important to be able to make more informed ‘Go’/’NoGo’ decisions early in 506 
clinical development and establish approaches to minimise risk and maximise the potential for 507 
success as a therapy progresses through the various stages of clinical development [50]. 508 
Demonstrating proof of target engagement/pharmacology in humans early in clinical development is 509 
crucial for reducing the risk involved in progressing novel drug therapeutics from Phase I 510 
safety/pharmacokinetic studies to later stage efficacy studies. In other fields, such as psychiatry, 511 
ascertaining the clinical pharmacology profile of novel drugs in early clinical development is a 512 
relatively common practise (e.g. PET ligand displacement studies) but is often overlooked in 513 
neurology therapeutics development, often due to lack of appropriate tools in clinical practice. 514 
Instead, compounds are progressed directly from Phase I/Ib safety/tolerability studies into Phase 515 
IIb/III efficacy studies. This strategy, particularly used in the narrow focus of the development of 516 
therapeutic antibodies, can contribute to poor decision making along the path of dementia drug 517 
development and testing leading to unsatisfactory outcomes in costly, late stage clinical trials. 518 
If achievable, being able to show drug target engagement and pharmacological consequence at the 519 
site of action serves a number of useful purposes: (1) it establishes that the therapeutic reaches and 520 
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engages the relevant target site of action; (2) determines the relevant pharmacological dose range 521 
for moving to later stage clinical trials; (3) it significantly reduces the risk of progressing a drug 522 
inappropriately  into late stage development; (4) it allows optimisation of dosing regimen based on 523 
established pharmacokinetic/pharmacodynamic relationships; and (5) it provides confidence that 524 
the mechanistic hypothesis, being targeted by the therapeutic, is truly being evaluated for efficacy in 525 
a population of people living with dementia. However, due to the costs associated with this early 526 
stage of development (particularly if new tools / approaches are needed) and a need for more rapid 527 
therapeutic development, there may be the potential to bypass these studies. Thus, it is important 528 
to find more collaborative risk and cost sharing approaches to show target engagement and drug 529 
pharmacology as these studies are critical in early drug development. To date, disease-modifying 530 
drugs that have reached Phase III clinical trials are primarily either small molecules or 531 
immunotherapies that target Aβ [34].  Behind this wave of Aβ targeted drugs are those that are 532 
directed towards tau [34] including those which reduce tau hyperphosphorylation, tau accumulation 533 
or prevent the spread of toxic tau species.  The current methodologies that demonstrate target 534 
engagement for tau are limited to cerebrospinal fluid (CSF) biomarker measurements, because of 535 
current uncertainty over off-target binding of PET ligands, even if heuristically binding of these 536 
ligands highly correlates with disease pathology and phenotype [51].  More recently, there has been 537 
a focus on targeting various neuro-inflammation pathways and processes.  It is important, therefore, 538 
to establish methodologies for measuring target engagement or proof of pharmacology across a 539 
range of these drug target classes, to facilitate a risk-reduced progression of such drugs to the next 540 
stage of development.  541 
A second area that is gathering momentum is the measurement of synaptic integrity and health, this 542 
can potentially provide a pharmacodynamic endpoint for many different therapeutic approaches, 543 
and also has the potential to serve as a relevant diagnostic biomarker.  Relevant methodologies 544 
include PET approaches for measuring synaptic density, and magnetoencephalography to measure 545 
circuit function including changes in oscillations [52].  One example of such an approach is the 546 
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synaptic vesicle glycoprotein 2A (SV2A) PET ligand (radioligand [53] (UCB-J) which is currently being 547 
evaluated as means of quantifying synaptic density. This radioligand ligand has been validated in 548 
humans including people with AD [53]. Initial studies suggest this approach may not only provide 549 
evidence of target engagement and early proof of mechanistic concept but could provide an 550 
approach to assessing prognostic drug efficacy as well as potentially being useful as a diagnostic for 551 
neurodegenerative diseases more generally. 552 
The discussions in this session focused on how to scope and facilitate collaboration in developing 553 
cost- and risk-sharing approaches to demonstrate target engagement, drug pharmacology and 554 
pharmacodynamic effects for target class mechanisms e.g. tau or neuroinflammation. This would 555 
span different drug approaches across multiple companies/partners. A potential approach is to 556 
establish public-private partnerships, similar to the DPUK’s Synaptic Health Theme, and the model 557 
used by ARUK’s Dementia Consortium for early drug discovery projects [7, 37]. The Consortium aims, 558 
through a cost-sharing and risk-sharing approach to translate fundamental academic research to 559 
early drug discovery programmes  for new dementia treatment [37].  560 
Regarding the exploration of new methodologies for measuring target-engagement and proof of 561 
pharmacology, one area that is underdeveloped in the UK is the sampling of CSF for relevant 562 
pharmacological endpoints. CSF is a useful resource in AD, given the breadth of analysis now 563 
available, for determining drug pharmacodynamic effects, pharmacology and target engagement as 564 
well as assessment of disease biomarkers, tracking disease progression and potentially improving 565 
early diagnosis [54]. However, unlike some other European countries, lumbar punctures are less 566 
commonly used in dementia clinical practice and dementia research. CSF sampling has recently been 567 
included in the updated National Institute of Care Excellence dementia guidelines, also showing the 568 
importance of this resource in a clinical setting [55]. Potential solutions to this issue would be to 569 
raise awareness of the high tolerability as well as utility of lumbar puncture, within both healthcare 570 
providers and the general public. However, it was noted that to achieve success in this area in the 571 
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UK, it is necessary to understand how to change the culture and training for CSF collections to 572 
become a routine procedure.  573 
The UK is a major partner in the international development of other new technologies for dementia 574 
research, including multiple UK centres participation in the EU Joint Programme - 575 
Neurodegenerative Disease Research (JPND) 2016-17 initiative for standardisation and 576 
harmonisation of new methods including magnetoencephalography, tau-PET, and ultrahigh field MRI 577 
[56]. UK and international support for these initiatives has succeeded in bringing expertise in to 578 
dementia research which had not previously been engaged. 579 
Summary of recommendations and suggested actions 580 
7.1.1. To scope and facilitate collaboration in developing cost- and risk-sharing approaches 581 
to demonstrate target engagement, proof of mechanism and proof of drug 582 
pharmacology for drug mechanisms common across multiple companies/partners  583 
7.1.1.1. Public-private partnership approach, similar to the cost-sharing, risk-sharing 584 
approach set-up for ARUK’s Dementia Consortium and DPUK  585 
7.1.1.2. To focus on common mechanisms for drugs currently in late stage preclinical 586 
development 587 
7.1.2.  Facilitate the use of CSF sampling to determine target engagement, proof of drug 588 
mechanism and effects on pharmacodynamic endpoints 589 
7.1.2.1. Understand how to change the culture, improve training, and encourage CSF 590 
collections to become a routine procedure  591 
7.1.3. Support advances in translating putative pharmacodynamic endpoints into useful 592 
clinical assays.  593 
 594 
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8. Innovative approaches to conducting clinical trials if we are able to detect 595 
diseases 10-15 years earlier than we do today 596 
How to approach clinical trials differently if detection/diagnosis is achieved earlier 597 
The majority of potential AD therapeutics have failed to show efficacy in Phase III clinical trials. At 598 
the time of writing, there have been no new drug approvals for treating AD since 2003. A potential 599 
reason for lack of efficacious and novel therapeutics in late stage clinical trials is that treatment 600 
intervention may be occurring at too late a stage in the disease process. There is widespread 601 
agreement amongst experts that if we were able to detect, and ultimately diagnose, disease at a 602 
much earlier stage then the chance of successful disease-modification, in addition to symptomatic 603 
therapies, would increase significantly.  To this end, researchers are looking towards developing 604 
tools that will allow early detection, diagnosis and treatment of diseases underpinning dementia at 605 
an early stage of disease. As a minimum these tools could help to efficiently and accurately triage at-606 
risk individuals for detailed clinical diagnosis but ideally, they would provide a tool that detects and 607 
subsequently diagnoses early stage disease, where perturbation of the disease process itself 608 
pharmacologically would have the greatest long-term therapeutic benefit.  609 
Several hurdles need to be overcome if such detection/diagnostic tools do become available, not 610 
least that the duration of Phase IIb/III clinical trials will increase significantly to allow measurement 611 
of clinical efficacy of drugs. Already, with the disease-modifying drugs currently in development, it is 612 
a challenge to conduct trials of sufficient duration to demonstrate a difference in the slope of 613 
cognitive decline. Early detection/diagnosis will compound this issue if existing cognitive outcomes 614 
retain primacy as measures of a beneficial effect, as trials will be required to run for even longer 615 
periods. If we are able to reliably detect/diagnose 10-15 years earlier, innovative approaches to how 616 
late stage clinical trials are conducted and implemented will be necessary which may include novel 617 
cognitive outcome measures more sensitive to neurodegenerative changes at their earliest phase 618 
[57]. Regulatory bodies are looking to provide conditional approval of dementia drugs based on 619 
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surrogate markers which may enable alternative means of collecting Phase III clinical trial data in a 620 
‘real-world’ setting utilising memory and brain health clinics for data collection [58]. This would 621 
allow for passive and active monitoring remotely using standard clinical endpoints but also digital 622 
approaches, generating ‘real-world’ data. To address this, a community-based trial protocol is 623 
currently being developed by ARUK to provide an exemplar of conducting real world (e.g. memory 624 
clinic-based) pivotal clinical trials for AD (‘virtual’ clinical trial). To achieve this, there needs to be 625 
increased engagement with regulators to inform guideline development and regulators need to be 626 
persuaded of the value of a virtual clinical trials approach.  627 
An alternative and complimentary strategy is to develop more sensitive tools for detecting cognitive 628 
change that can be used at-scale. Many outcome measures use well established technologies that 629 
have been developed for use specifically in a clinical context.  These measures are unsuitable for use 630 
in large pre-clinical populations. A strong case can be made for a new generation of digital cognitive 631 
phenotyping tools that can detect early changes indicating increased clinical risk. This is an 632 
opportunity for stakeholders to collaborate in developing standard tools that are understood and 633 
accepted by regulators, industry, and academia. 634 
If it is possible to detect AD much earlier than current methods allow, an important factor to 635 
consider is the impact for individuals who have the disease detected and their families. Current trials 636 
use different outcome measures (clinical, functional and biological) to determine the efficacy of the 637 
treatment, however these outcomes have not been determined patients and their carers but are 638 
instead an objective measure of clinical symptoms. Therefore, it will be extremely important to 639 
understand the preferred outcomes of people living with dementia for early stages of disease, which 640 
can then inform drug development and provide additional endpoints for clinical trials. To this aim, 641 
ARUK has begun to explore an outcomes project in collaboration with researchers, people affected 642 
by dementia, clinicians, and regulators [59]. It is important to continue supporting projects to 643 
understand the outcomes people living with dementia prefer and persuade both the research 644 
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community and regulators of the importance of these in informing clinical trial design and conduct. 645 
The AD community are not alone in facing these issues. The EU JPND supported a cross-disciplinary 646 
working group, the Presymptomatic Neurodegeneration Initiative, where researchers, funders and 647 
regulators considered analogous challenges in AD, frontotemporal dementia, motor neuron disease, 648 
Huntington’s disease and other conditions [60]. 649 
Conducting longer clinical trials will also have implications for data protection regulation. Innovators 650 
have patent protection as well as data exclusivity for several years, however, with treatments 651 
shifting to earlier stages of the disease and the possibility that patents may not survive for many 652 
years after drug approval due to longer clinical trials, there may be a need to evolve data protection 653 
regulation and patent life in line with developments in approaches to treatment.    654 
Summary of recommendations and suggested actions 655 
8.1.1.  If we detect neurodegenerative diseases 10-15 years earlier, propose and 656 
theoretically validate a new approach for conducting and implementing late stage, 657 
pivotal clinical trials 658 
8.1.1.1. Develop a community-based trial protocol to provide an exemplar of 659 
conducting a real world (e.g. memory clinic) pivotal clinical trial for AD  660 
8.1.1.2. Engage with regulators and relevant bodies to inform the development of an 661 
innovative approach to the conduct of late stage clinical trials including digital 662 
cognitive phenotyping strategies 663 
8.1.1.3. Educate regulators regarding the value of a ’virtual’ clinical trials approach 664 
8.1.2. Understand outcomes people living with dementia prefer for early stages of disease, 665 
which can inform drug development and provide additional endpoints for clinical trials  666 
8.1.3. Work with relevant stakeholders to evolve data protection regulations in line with 667 
the shift to treating earlier in the disease course. 668 
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9.  Conclusions 669 
The national and global objective of delivering a disease-modifying treatment for dementia by 2025, 670 
as well as the development of improved symptomatic therapies, will require a multi-faceted 671 
approach to broaden current research areas by addressing prevention, earlier detection/diagnosis, 672 
disease mechanisms and the design of clinical trials. Specific recommendations and actions detailed 673 
in this paper include: 674 
 Using a more integrated biology approach to translate genetic data into cell biology  675 
 Map resilience and vulnerability by brain region using an ‘omics’-based approach  676 
 Include requirements in funding applications for robust target validation in pre-clinical 677 
models and humans 678 
 Using multiple data sources to increase reliability and reproducibility of findings  679 
 Focus on demonstrating proof of mechanism/pharmacology/efficacy in clearly defined 680 
populations (e.g. Down’s syndrome) initially and subsequently expanding to the wider AD 681 
population 682 
 Develop cost-and risk-sharing approaches to demonstrate target engagement   683 
 Developing a community-based clinical trial protocol to promote a paradigm shift in how 684 
late stage clinical trials could be conducted.  685 
In addition to specific recommendations for individual themes, there were also a number of 686 
recommendations that were relevant across all the themes. These include incentivising 687 
collaborations both within the dementia field and with other fields, consideration of data sharing, 688 
interoperability and centralised databases, promoting and supporting the sharing of research tools, 689 
changing the incentives in academia and industry to encourage a more collaborative approach and 690 
raising education and awareness of the public, research community and clinicians. The overarching 691 
resolution is to find additional ways to incentivise collaboration, particularly interdisciplinary 692 
collaboration, to standardise approaches, to re-think clinical approaches to early and late stage 693 
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clinical trials and to efficiently and comprehensively share data and samples at all levels across the 694 
scientific community.  All are essential to accelerate the progress towards the goal of developing an 695 
effective treatment for AD by 2025.  696 
Acknowledgements 697 
We thank Eric Karran for helpful discussions and advice. 698 
Funding 699 
This work was supported by Alzheimer’s Research UK. 700 
  701 
30 
 
References 702 
[1] Cappa SF. The Quest for an Alzheimer Therapy. Front Neurol 2018;9:108. 703 
[2] Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. World Alzheimer 704 
Report 2016: improving healthcare for people living with dementia: coverage, quality and costs now 705 
and in the future. London: Alzheimer's Disease International (ADI). 2016. Available at: 706 
https://www.alz.co.uk/research/WorldAlzheimerReport2016.pdf. Accessed March 20, 2019. 707 
[3] Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW, et al. Drug development in 708 
Alzheimer's disease: the path to 2025. Alzheimers Res Ther 2016;8:39. 709 
[4] Agatonovic-Kustrin S, Kettle C, Morton DW. A molecular approach in drug development for 710 
Alzheimer's disease. Biomed Pharmacother 2018;106:553-65. 711 
[5] G8 dementia summit: Global action against dementia - 11th December 2013. Available at: 712 
https://www.gov.uk/government/publications/g8-dementia-summit-global-action-against-713 
dementia/g8-dementia-summit-global-action-against-dementia-11-december-2013. Accessed March 714 
20, 2019. 715 
[6] Prime Minister's Challenge on Dementia 2020.  Available at: 716 
https://www.gov.uk/government/publications/prime-ministers-challenge-on-dementia-2020/prime-717 
ministers-challenge-on-dementia-2020#executive-summary. Accessed March 20, 2019. 718 
[7] Dementias Platform UK. Available at: https://www.dementiasplatform.uk/. Accessed March 719 
20, 2019. 720 
[8] The Dementia Discovery Fund. Available at: https://theddfund.com. Accessed March 20, 721 
2019. 722 
[9] Drug Discovery Alliance.  Available at: https://www.alzheimersresearchuk.org/our-723 
research/what-we-do/big-initiatives/drug-discovery-alliance/. Accessed March 20, 2019. 724 
[10] UK Dementia Research Institute (UK DRI).  Available at: https://ukdri.ac.uk. Accessed March 725 
20, 2019. 726 
[11] Rosenberg RN, Lambracht-Washington D, Yu G, Xia W. Genomics of Alzheimer Disease: A 727 
Review. JAMA Neurol 2016;73(7):867-74. 728 
[12] Huang X, Liu H, Li X, Guan L, Li J, Tellier LCAM, et al. Revealing Alzheimer's disease genes 729 
spectrum in the whole-genome by machine learning. BMC Neurol 2018;18(1):5. 730 
[13] Open Targets. A partnership to transform drug discovery through the systematic 731 
identification and prioritisation of targets. Available at: https://www.opentargets.org/. Accessed 732 
March 20, 2019. 733 
[14] Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk 734 
from complex variation of complement component 4. Nature 2016;530(7589):177-83. 735 
[15] Research Excellence Framework. Available at: https://www.ref.ac.uk. Accessed March 20, 736 
2019. 737 
[16] NIMA: Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and 738 
Alzheimer’s Disease. Available at: https://www.neuroimmunology.org.uk. Accessed March 20, 2019. 739 
[17] Magalingam KB, Radhakrishnan A, Ping NS, Haleagrahara N. Current Concepts of 740 
Neurodegenerative Mechanisms in Alzheimer's Disease. Biomed Res Int 2018;2018:3740461. 741 
[18] Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular  mechanisms of 742 
dementia. J Cereb Blood Flow Metab 2016;36(1):172-86. 743 
[19] Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid 744 
hypothesis of Alzheimer's disease. Acta Neuropathol Commun 2014;2:135. 745 
[20] Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer 746 
disease neuropathologic changes with cognitive status:  a review of the literature. J Neuropathol Exp 747 
Neurol 2012;71(5):362-81. 748 
[21] Jagust W. Is amyloid-β harmful to the brain? Insights from human imaging studies. Brain 749 
2016;139(Pt 1):23-30. 750 
31 
 
[22] Farías G, Cornejo A, Jiménez J, Guzmán L, Maccioni RB. Mechanisms of tau self-aggregation 751 
and neurotoxicity. Curr Alzheimer Res 2011;8(6):608-14. 752 
[23] Muratore CR, Zhou C, Liao M, Fernandez MA, Taylor WM, Lagomarsino VN, et al. Cell-type 753 
Dependent Alzheimer's Disease Phenotypes: Probing the Biology of Selective Neuronal Vulnerability. 754 
Stem Cell Reports 2017;9(6):1868-84. 755 
[24] Freer R, Sormanni P, Vecchi G, Ciryam P, Dobson CM, Vendruscolo M. A protein homeostasis 756 
signature in healthy brains recapitulates tissue vulnerability to Alzheimer's disease Sci Adv 757 
2016;2(8):e1600947. 758 
[25] Fu H, Possenti A, Freer R, Nakano Y, Villegas NCH, Tang M, et al. A tau homeostasis signature 759 
is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. Nat 760 
Neurosci 2019;22(1):47-56. 761 
[26] Leanza G, Gulino R, Zorec R. Noradrenergic Hypothesis Linking Neurodegeneration-Based 762 
Cognitive Decline and Astroglia Front Mol Neurosci 2018;11:254. 763 
[27] Aging Brain. Aging, Dementia and TBI Study.  Available at: http://aging.brain-map.org/. 764 
Accessed March 20, 2019. 765 
[28] Allen Brain Map. Accelerating progress toward understanding the brain.  Available at: 766 
https://www.brain-map.org/. Accessed March 20, 2019. 767 
[29] NIH National Institute on Aging. Recommendations from the NIH AD Research Summit 2018.  768 
Available at: https://www.nia.nih.gov/research/administration/recommendations-nih-ad-research-769 
summit-2018. Accessed March 20, 2019. 770 
[30] Sancesario GM, Bernardini S. Alzheimer's disease in the omics era. Clin Biochem 2018;59:9-771 
16 772 
[31] Henstridge CM, Hyman BT, Spires-Jones TL. Beyond the neuron-cellular interactions early in 773 
Alzheimer disease pathogenesis. Nat Rev Neurosci 2019;20(2):94-108. 774 
[32] UK Brain Banks Network. Available at: https://mrc.ukri.org/research/facilities-and-775 
resources-for-researchers/brain-banks/. Accessed March 20, 2019. 776 
[33] Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, et al. Collaboration for 777 
Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's 778 
disease trials. Alzheimers Dement 2016;12(5):631-2. 779 
[34] Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2018. 780 
Alzheimers Dement (N Y) 2018;4:195-214. 781 
[35] ARRIVE guidelines.  Available at: https://www.nc3rs.org.uk/arrive-guidelines. Accessed 782 
March 20, 2019. 783 
[36] Committee on Best Practice in Data Analysis and Sharing (COBIDAS).  Available at: 784 
https://www.humanbrainmapping.org/i4a/pages/index.cfm?pageid=3728. Accessed March 20, 785 
2019. 786 
[37] Dementia Consortium.  Available at: http://www.dementiaconsortium.org/. Accessed March 787 
20, 2019. 788 
[38] Accelerating Medicines Partnership - Alzheimer's Disease (AMP-AD).  Available at: 789 
https://www.nia.nih.gov/research/amp-ad. Accessed March 20, 2019. 790 
[39] NEWMEDS.  Available at: https://www.newmeds-europe.com/. Accessed March 20, 2019. 791 
[40] Smith MM, Clarke EC, Little CB. Considerations for the design and execution of protocols for 792 
animal research and treatment to improve reproducibility and standardization: "DEPART well-793 
prepared and ARRIVE safely". Osteoarthritis Cartilage 2017;25(3):354-63. Accessed March 20, 2019. 794 
[41] A Field Guide to Working with Mouse Models of Huntington’s Disease.  Available at: 795 
https://chdifoundation.org/wp-content/uploads/HD_Field_Guide_040414.pdf. Accessed March 20, 796 
2019. 797 
[42] Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few 798 
candidates, frequent failures. Alzheimers Res Ther 2014;6(4):37. 799 
[43] Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and 800 
dementia of Alzheimer's disease in Down's syndrome Ann Neurol 1985;17(3):278-82. 801 
32 
 
[44] Calderon-Garcidueñas AL, Duyckaerts C. Alzheimer disease. Handb Clin Neurol 802 
2017;145:325-37. 803 
[45] Dementias Platform UK. Deep and Frequent Phenotyping Study.  Available at: 804 
https://www.dementiasplatform.uk/our-impact/a-step-forward-for-experimental-medicine/dpuk-805 
and-experimental-medicine/deep-and-frequent-phenotyping-study. Accessed March 20, 2019. 806 
[46] European Prevention of Alzheimer’s Dementia Consortium (EPAD).  Available at: http://ep-807 
ad.org/. Accessed March 20, 2019. 808 
[47] Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct 809 
cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 810 
2009;132(Pt 11):2958-69. 811 
[48] Premi E, Grassi M, van Swieten J, Galimberti D, Graff C, Masellis M, et al. Cognitive reserve 812 
and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a 813 
GENFI study. Brain 2017;140(6):1784-91. 814 
[49] Gates B. Why I'm digging deep into Alzheimer's.  Available at: 815 
https://www.gatesnotes.com/Health/Digging-Deep-Into-Alzheimers. Accessed March 20, 2019. 816 
[50] Steinmetz KL, Spack EG. The basics of preclinical drug development for neurodegenerative 817 
disease indications. BMC Neurol 2009;9 Suppl 1:S2. 818 
[51] Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET 819 
patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 2016;139(Pt 820 
5):1551-67. 821 
[52] Sami S, Williams N, Hughes LE, Cope TE, Rittman T, Coyle-Gilchrist ITS, et al. 822 
Neurophysiological signatures of Alzheimer's disease and frontotemporal lobar degeneration: 823 
pathology versus phenotype. Brain 2018;141(8):2500-10. 824 
[53] Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, et al. Assessing Synaptic 825 
Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic 826 
Imaging. JAMA Neurol 2018;75(10):1215-24. 827 
[54] Khan TK. An Algorithm for Preclinical Diagnosis of Alzheimer's Disease. Front Neurosci 828 
2018;12:275. 829 
[55] NICE. Dementia: assessment, management and support for people living with dementia and 830 
their carers.  Available at: 831 
https://www.nice.org.uk/guidance/ng97/chapter/Recommendations#diagnosis. Accessed March 20, 832 
2019. 833 
[56] EU Joint Program - Neurodegenerative Disease Research (JPND).  Available at: 834 
http://www.neurodegenerationresearch.eu/. Accessed March 20, 2019. 835 
[57] Ritchie K, Ropacki M, Albala B, Harrison J, Kaye J, Kramer J, et al. Recommended cognitive 836 
outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of 837 
Alzheimer's Dementia project. Alzheimers Dement 2017;13(2):186-95. 838 
[58] Ritchie CW, Russ TC, Banerjee S, Barber B, Boaden A, Fox NC, et al. The Edinburgh 839 
Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. 840 
Alzheimers Res Ther 2017;9(1):85. 841 
[59] Saunders S, Muniz-Terrera G, Watson J, Clarke CL, Luz S, Evans AR, et al. Participant 842 
outcomes and preferences in Alzheimer's disease clinical trials: The electronic Person-Specific 843 
Outcome Measure (ePSOM) development program. Alzheimers Dement (N Y) 2018;4:694-702. 844 
[60] Developing a methodological framework for trials in presymptomatic neurodegenerative 845 
disease – the Presymptomatic Neurodegeneration Initiative (PreNI).  Available at: 846 
http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/02/PreNI.pdf. Accessed 847 
March 20, 2019. 848 
 849 
